Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Equine Vet Sci ; 34(11-12): 1348-1351, 2014.
Article in English | MEDLINE | ID: mdl-33727764

ABSTRACT

A case of encephalitis of unknown origin in the horse was investigated. Postmortem examination findings revealed a nonsuppurative granulomatous meningoencephalitis in the right hemisphere of the cerebral cortex. Testing for West Nile virus, equine herpes virus, equine infectious anemia, Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona were negative. The horse had a titer for Encephalitozoon cuniculi, and sections from the affected area of the brain tested positive for the organism using both polymerase chain reaction (PCR) and immunohistochemistry. Amplicons generated using PCR were sequenced, and E. cuniculi genotype II was identified. This is the first case of E. cuniculi genotype II associated with encephalitis in the horse.

2.
Mod Pathol ; 18(6): 844-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15696126

ABSTRACT

CDC6 and MCM5 play essential roles in eukaryotic DNA replication. Several studies have highlighted the potential of these proteins as molecular markers of dysplastic and malignant cells in histopathological diagnosis. The mode of expression of CDC6 and MCM5 mRNA and their significance in normal, dysplastic and malignant cervical cells remains to be elucidated. Using a quantitative real-time RT PCR assay, we compared CDC6 and MCM5 mRNA expression in normal cervical epithelium, cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Our study cohort comprised 20 normal cervical biopsies, 20 CIN3 and eight invasive squamous cell carcinomas. All samples were formalin fixed and paraffin embedded. Total RNA was extracted and analysed for expression of GAPDH, CDC6 and MCM5 using real-time quantitative TaqMan RT-PCR. A linear increase in MCM5 and CDC6 mRNA expression is observed in normal cervix, CIN3 and invasive cervical carcinoma. The overall difference in MCM5 mRNA expression in the normal cervix, CIN3 and invasive cohort groups is highly statistically significant (P=0.001). An increase in CDC6 mRNA expression in CIN3 and invasive cervical squamous cell carcinoma was observed; however, the overall difference between cohort groups was not found to be statistically significant (P=0.104). Increased transcription of MCM5 and CDC6 occurs as a consequence of cervical neoplastic progression. This pattern of increased mRNA expression in CIN3 and invasive cervical carcinoma directly correlates with findings at the phenotypic protein expression level. This study further confirms the importance of MCM5 and CDC6 in malignant transformation and in the pathogenesis of cervical dysplasia.


Subject(s)
Carcinoma, Squamous Cell/pathology , Cell Cycle Proteins/genetics , Nuclear Proteins/genetics , RNA, Messenger/metabolism , Uterine Cervical Dysplasia/pathology , Uterine Cervical Neoplasms/pathology , Carcinoma, Squamous Cell/genetics , Female , Humans , Neoplasm Invasiveness , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction , Uterine Cervical Neoplasms/genetics , Uterine Cervical Dysplasia/genetics
3.
Cancer Detect Prev ; 27(1): 47-54, 2003.
Article in English | MEDLINE | ID: mdl-12600417

ABSTRACT

The aim of this study was to use the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) assay to determine the response of 17 endometrial and 27 cervical tumours to cytotoxic drugs. Tumour samples were taken at surgery and cultured using the explant technique. Cells were incubated with chemotherapy drugs. The MTS cytotoxicity assay was carried out to ascertain the response to the drugs and correlated retrospectively to the clinical outcome. Tumours of similar stage and grade displayed heterogeneity in their responses to the drugs. A total of 88 of 90 tumours (97.8%), including data from an earlier study of 44 ovarian tumour samples yielded chemosensitivity data. A total of 45 specimens were evaluable for in vitro-in vivo correlations. In vitro sensitivity was associated with clinical response in 26 of 30 patients and in vitro resistance with progressive disease or death in 14 of 15 patients. A randomised prospective trial should be carried out to validate chemosensitivity/resistance testing.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm , Genital Neoplasms, Female/drug therapy , Toxicity Tests/methods , Cell Survival/drug effects , Cells, Cultured , Cisplatin/pharmacology , Drug Screening Assays, Antitumor/methods , Drug Therapy, Combination , Endometrial Neoplasms/drug therapy , Female , Fluorouracil/pharmacology , Humans , Neoplasm Staging , Paclitaxel/pharmacology , Retrospective Studies , Tetrazolium Salts , Topotecan/pharmacology , Treatment Outcome , Uterine Cervical Neoplasms/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...